Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer. 1995

R V Iaffaioli, and A Tortoriello, and G Facchini, and M Santangelo, and L Bucci, and L Fei, and N Di Martino, and G Mantovani, and F Caponigro
Istituto di Medicina Interna, Universitá di Cagliari, Italy.

44 patients with advanced breast cancer were treated with high-dose epirubicin (130 mg/sqm), because of its steep dose-response curve. Lonidamine and alpha interferon were administered as well with the aim of increasing epirubicin uptake and overcoming drug resistance. Granulocyte-colony stimulating factor support was provided. 14 complete responses and 22 partial responses were observed in 40 evaluable patients for a 90% overall response rate. Median duration of response was 12 months for complete responders, 7 months for partial responders. In two cases the complete response has lasted for more than two years. Myelosuppression, infection, and cardiac toxicity were the main treatment-related toxic effects. These results are encouraging enough to justify a randomized comparison of our chemotherapy program with standard regimens used in advanced breast cancer.

UI MeSH Term Description Entries
D007191 Indazoles A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES. Indazole
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R V Iaffaioli, and A Tortoriello, and G Facchini, and M Santangelo, and L Bucci, and L Fei, and N Di Martino, and G Mantovani, and F Caponigro
January 1996, European journal of cancer (Oxford, England : 1990),
R V Iaffaioli, and A Tortoriello, and G Facchini, and M Santangelo, and L Bucci, and L Fei, and N Di Martino, and G Mantovani, and F Caponigro
January 1994, European journal of cancer (Oxford, England : 1990),
R V Iaffaioli, and A Tortoriello, and G Facchini, and M Santangelo, and L Bucci, and L Fei, and N Di Martino, and G Mantovani, and F Caponigro
October 1995, Australian and New Zealand journal of medicine,
R V Iaffaioli, and A Tortoriello, and G Facchini, and M Santangelo, and L Bucci, and L Fei, and N Di Martino, and G Mantovani, and F Caponigro
January 1991, Cancer chemotherapy and pharmacology,
R V Iaffaioli, and A Tortoriello, and G Facchini, and M Santangelo, and L Bucci, and L Fei, and N Di Martino, and G Mantovani, and F Caponigro
February 1986, Cancer treatment reports,
R V Iaffaioli, and A Tortoriello, and G Facchini, and M Santangelo, and L Bucci, and L Fei, and N Di Martino, and G Mantovani, and F Caponigro
February 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R V Iaffaioli, and A Tortoriello, and G Facchini, and M Santangelo, and L Bucci, and L Fei, and N Di Martino, and G Mantovani, and F Caponigro
January 1994, Acta oncologica (Stockholm, Sweden),
R V Iaffaioli, and A Tortoriello, and G Facchini, and M Santangelo, and L Bucci, and L Fei, and N Di Martino, and G Mantovani, and F Caponigro
January 1992, European journal of cancer (Oxford, England : 1990),
R V Iaffaioli, and A Tortoriello, and G Facchini, and M Santangelo, and L Bucci, and L Fei, and N Di Martino, and G Mantovani, and F Caponigro
January 2000, Cancer,
R V Iaffaioli, and A Tortoriello, and G Facchini, and M Santangelo, and L Bucci, and L Fei, and N Di Martino, and G Mantovani, and F Caponigro
November 1984, Cancer,
Copied contents to your clipboard!